Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EYPT 
Eyepoint Pharmaceuticals Inc (EYPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: EYPT (4-star) is a SELL. SELL since 3 days. Simulated Profits (6.54%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $34.42
1 Year Target Price $34.42
| 9 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 333.38% | Avg. Invested days 54 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 939.16M USD | Price to earnings Ratio - | 1Y Target Price 34.42 |
Price to earnings Ratio - | 1Y Target Price 34.42 | ||
Volume (30-day avg) 13 | Beta 1.97 | 52 Weeks Range 3.91 - 14.91 | Updated Date 10/18/2025 |
52 Weeks Range 3.91 - 14.91 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1166.83% |
Management Effectiveness
Return on Assets (TTM) -37.79% | Return on Equity (TTM) -73.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 696602237 | Price to Sales(TTM) 18.1 |
Enterprise Value 696602237 | Price to Sales(TTM) 18.1 | ||
Enterprise Value to Revenue 13.42 | Enterprise Value to EBITDA -11.49 | Shares Outstanding 80753269 | Shares Floating 42632302 |
Shares Outstanding 80753269 | Shares Floating 42632302 | ||
Percent Insiders 3.48 | Percent Institutions 101.23 |
Upturn AI SWOT
Eyepoint Pharmaceuticals Inc
Company Overview
History and Background
EyePoint Pharmaceuticals, Inc. (EYPT) was founded in 1987 (formerly pSivida Corp) and focuses on developing and commercializing innovative ophthalmic products for severe eye disorders. It has transitioned from a drug delivery technology company to a commercial-stage pharmaceutical company.
Core Business Areas
- Commercial Products: Includes marketed products such as YUTIQ (fluocinolone acetonide intravitreal implant) for chronic non-infectious uveitis affecting the posterior segment of the eye and DEXYCU (dexamethasone intraocular suspension) for postoperative inflammation.
- Pipeline Development: Focuses on developing sustained-release drug delivery systems for treating various eye diseases, including wet age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. This includes products under development.
Leadership and Structure
EyePoint Pharmaceuticals is led by a management team with experience in ophthalmology, drug development, and commercialization. The organizational structure includes departments for research and development, clinical trials, manufacturing, and sales and marketing.
Top Products and Market Share
Key Offerings
- YUTIQ: YUTIQ is a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Competitors include corticosteroids, immunosuppressants and biologics. Market share is not precisely available, but it is a key product for EyePoint. Revenue derived from product sales and royalties. Competitors are AbbVie (Humira), Bausch + Lomb (Lotemax SM), Alimera Sciences (Iluvien).
- DEXYCU: DEXYCU is a dexamethasone intraocular suspension indicated for the treatment of postoperative inflammation following cataract surgery. The market share is estimated to be small based on the size and revenue. Competitors include topical steroids. Ocular Therapeutix (Dextenza), ImprimisRx (Dex-T).
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical industry is characterized by growing demand due to an aging population and increasing prevalence of eye diseases such as AMD, diabetic retinopathy, and glaucoma. There is significant innovation in drug delivery and novel therapies.
Positioning
EyePoint Pharmaceuticals is positioned as a specialty pharmaceutical company focused on sustained-release drug delivery systems for treating chronic eye diseases. Competitive advantages include its proprietary Durasert technology and targeted therapies.
Total Addressable Market (TAM)
The global ophthalmology market is expected to reach over $40 billion by 2028. Eyepoint Pharmaceuticals is positioned to capture a portion of this TAM through its current product offerings and pipeline development.
Upturn SWOT Analysis
Strengths
- Proprietary Durasert sustained-release technology
- Approved products with revenue potential
- Experienced management team
- Focus on unmet needs in ophthalmology
Weaknesses
- Reliance on key products
- Competition from larger pharmaceutical companies
- Dependence on regulatory approvals
- Limited financial resources compared to major players
Opportunities
- Expansion of product pipeline
- Strategic partnerships and collaborations
- Geographic expansion
- Development of new applications for Durasert technology
Threats
- Regulatory hurdles and clinical trial failures
- Competition from generics and biosimilars
- Changes in reimbursement policies
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- ALIM
- VRX
- AGN
Competitive Landscape
EyePoint Pharmaceuticals operates in a competitive landscape with larger pharmaceutical companies and specialty players. Advantages include their Durasert technology, while disadvantages include limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product sales and development milestones, but influenced by market conditions.
Future Projections: Future growth projections depend on successful pipeline development, commercial execution, and strategic partnerships.
Recent Initiatives: Recent strategic initiatives include clinical trials for new indications, commercial expansion, and collaborations with other companies.
Summary
EyePoint Pharmaceuticals is a specialty pharmaceutical company with a focus on ophthalmic products. Its proprietary Durasert technology offers a competitive advantage. Key challenges include competition from larger players and the need to successfully develop and commercialize pipeline products. Financial performance is volatile, and shareholder returns are dependent on future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eyepoint Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2005-01-27 | President, CEO & Director Dr. Jay S. Duker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 165 | Website https://eyepointpharma.com |
Full time employees 165 | Website https://eyepointpharma.com | ||
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.